Division of Hematology,
T Cell Engineering
My research is focused on adoptive cellular therapy and allogeneic transplantation for hematological malignancies. After completing a fellowship in hematology and medical oncology in Japan, I joined the translational research program of the Nagoya University Graduate School of Medicine, where I trained for three years. My work involved the development of inducible chimeric antigen receptor (CAR) T cell therapy for acute lymphoblastic leukemia. An inducible model could reduce CART cell therapy-related toxicities such as off-target effects. I joined Dr. Kenderian’s laboratory at the Mayo Clinic in April 2017. I have led numerous innovative projects focused on developing CART cell therapies that target the microenvironment of hematological malignancies, non-invasively imaging CART cells with positron emission tomography and a combination of CART cell therapy with small molecule inhibitors.
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Blood Feb, 2019 | Pubmed ID: 30463995
Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.
Immunotherapy Jul, 2019 | Pubmed ID: 31161844
[Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy].
[Rinsho ketsueki] The Japanese journal of clinical hematology , 2019 | Pubmed ID: 31167996
Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a 'graft versus host'-like syndrome and poor outcomes.
Bone marrow transplantation 09, 2020 | Pubmed ID: 32161319
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
Mayo Clinic proceedings 11, 2020 | Pubmed ID: 33153629
Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Molecular therapy : the journal of the American Society of Gene Therapy 04, 2021 | Pubmed ID: 33388419
Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies.
Leukemia & lymphoma 09, 2021 | Pubmed ID: 33682608
CART cell imaging: Paving the way for success in CART cell therapy.
Molecular therapy oncolytics Mar, 2021 | Pubmed ID: 33816781
Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Cancer immunology research 09, 2021 | Pubmed ID: 34244299
Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.
Blood Jan, 2022 | Pubmed ID: 35090171